Matt Whitmire - Janux Therapeutics Vice Finance
| JANX Stock | USD 46.39 1.61 3.35% |
Executive
Matt Whitmire is Vice Finance of Janux Therapeutics
| Address | 10955 Vista Sorrento Parkway, San Diego, CA, United States, 92130 |
| Phone | 858 751 4493 |
| Web | https://www.januxrx.com |
Janux Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.0993) % which means that it has lost $0.0993 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1205) %, meaning that it created substantial loss on money invested by shareholders. Janux Therapeutics' management efficiency ratios could be used to measure how well Janux Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.16 in 2024. Return On Capital Employed is likely to rise to -0.19 in 2024. At this time, Janux Therapeutics' Net Tangible Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 32.7 M in 2024, whereas Total Assets are likely to drop slightly above 251.1 M in 2024.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Dr MBA | Acrivon Therapeutics, Common | N/A | |
| Gopal MBBS | Rezolute | N/A | |
| Terry Evans | Fennec Pharmaceuticals | N/A | |
| Stephen Yu | Aerovate Therapeutics | N/A | |
| Sanjeev Khindri | Aerovate Therapeutics | N/A | |
| Yung MD | Keros Therapeutics | 48 | |
| Sarah Foster | Mineralys Therapeutics, Common | N/A | |
| Dr MS | Fennec Pharmaceuticals | N/A | |
| Robert McKean | Mineralys Therapeutics, Common | N/A | |
| Jeffrey Fellows | Mineralys Therapeutics, Common | N/A | |
| Marc MD | Edgewise Therapeutics | 67 | |
| Renate Gloggner | Molecular Partners AG | 54 | |
| Marianna Zipeto | Champions Oncology | N/A | |
| Katharine CPA | Acrivon Therapeutics, Common | N/A | |
| Tricia Glover | Harmony Biosciences Holdings | N/A | |
| Minji MBA | Mineralys Therapeutics, Common | N/A | |
| Anne DVM | Molecular Partners AG | N/A | |
| John Moore | Edgewise Therapeutics | 60 | |
| BSc MD | Aerovate Therapeutics | N/A | |
| Cate McCanless | Harmony Biosciences Holdings | N/A | |
| Robert Andrade | Fennec Pharmaceuticals | 49 | |
Management Performance
| Return On Equity | -0.12 | ||||
| Return On Asset | -0.0993 |
Janux Therapeutics Leadership Team
Elected by the shareholders, the Janux Therapeutics' board of directors comprises two types of representatives: Janux Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Janux. The board's role is to monitor Janux Therapeutics' management team and ensure that shareholders' interests are well served. Janux Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Janux Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| David Campbell, CEO President | ||
| Brenda Vreeswyk, Head Resources | ||
| Byron JD, Chief Officer | ||
| Wayne MD, Chief Officer | ||
| Tommy Diraimondo, Director Research | ||
| Matt Whitmire, Vice Finance | ||
| Charles Winter, Manufacturing Chemistry | ||
| CFA CPA, Acting Officer | ||
| CPA CFA, Acting Officer | ||
| Andy Meyer, Chief Officer | ||
| James Pennington, General Counsel | ||
| Maria Dobek, Principal Accounting |
Janux Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Janux Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.12 | ||||
| Return On Asset | -0.0993 | ||||
| Operating Margin | (81.64) % | ||||
| Current Valuation | 1.8 B | ||||
| Shares Outstanding | 52.48 M | ||||
| Shares Owned By Insiders | 7.74 % | ||||
| Shares Owned By Institutions | 94.58 % | ||||
| Number Of Shares Shorted | 4.19 M | ||||
| Price To Book | 3.71 X | ||||
| Price To Sales | 186.58 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Janux Stock Analysis
When running Janux Therapeutics' price analysis, check to measure Janux Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Janux Therapeutics is operating at the current time. Most of Janux Therapeutics' value examination focuses on studying past and present price action to predict the probability of Janux Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Janux Therapeutics' price. Additionally, you may evaluate how the addition of Janux Therapeutics to your portfolios can decrease your overall portfolio volatility.